In an elderly female patient with a history of heart failure with reduced ejection fraction who is admitted with volume overload and now has acute kidney injury (creatinine increased from 1.28 to 2.39 mg/dL), how should diuresis be managed?

Managing Diuresis in HFrEF with AKI and Volume Overload

Continue aggressive diuresis despite the AKI—in this clinical scenario with severe volume overload, the rising creatinine likely reflects venous congestion rather than true tubular injury, and achieving decongestion will ultimately improve both cardiac output and renal perfusion. 1, 2

Understanding the Paradox: Why Diurese Despite Rising Creatinine?

Your patient's creatinine has increased significantly (1.28→2.39 mg/dL, an 87% rise), which exceeds the 30% threshold typically used to define worsening renal function 2. However, this does not mean you should stop diuresis. Here's the critical distinction:

The Cardiorenal Syndrome Context

In severe volume overload with HFrEF, renal venous congestion is often the primary driver of kidney dysfunction 3, 4. The elevated right-sided pressures impair renal perfusion more than low cardiac output does. Paradoxically, aggressive decongestion—even when it temporarily raises creatinine—improves long-term renal function by relieving venous congestion and allowing the heart to move leftward on the Starling curve, thereby increasing stroke volume 2.

Key principle: Persistent volume overload is more dangerous than transient creatinine elevation during effective decongestion 1.

Practical Diuresis Strategy

Step 1: Assess Volume Status and Perfusion Daily

Monitor these parameters closely 2:

• Body weight (target 0.5-1 kg daily loss)
• Jugular venous pressure (goal: normalize)
• Peripheral edema
• Blood pressure (ensure adequate perfusion)
• Urine output
• Electrolytes and creatinine (daily in hospital, then every 1-3 days)

Step 2: Optimize Intravenous Loop Diuretic Delivery

Use continuous IV furosemide infusion rather than bolus dosing 2. This approach is superior to repeated large boluses and at least as safe, providing more consistent diuresis with potentially less renal injury.

Dosing approach:

• Start with 40-120 mg IV furosemide (or equivalent) 2
• If inadequate response, escalate to continuous infusion
• Many patients require high doses due to reduced GFR and distal tubular sodium reabsorption 2

Step 3: Address Diuretic Resistance

If response is inadequate (common with GFR reduction), employ these strategies 2:

1. Add a thiazide-type diuretic (Class IIa, Level B recommendation):

   • Metolazone 2.5-5 mg daily
   • Hydrochlorothiazide 25-50 mg twice daily
   • This blocks distal tubular sodium reabsorption 5
   • Monitor electrolytes closely to avoid severe hypokalemia and hypomagnesemia

2. Ensure adequate electrolyte repletion:

   • Correct magnesium and potassium deficiencies, which impair diuretic response 2

3. Consider continuous infusion over boluses (already mentioned above)

Step 4: Medication Review and Adjustment

Critical medication considerations 2:

• Review and potentially hold nephrotoxic agents: NSAIDs, COX-2 inhibitors

• ACE inhibitors/ARBs/spironolactone:

  • If creatinine rises >50% from baseline or exceeds 250 μmol/L (2.8 mg/dL), consider dose reduction or temporary hold 2
  • Your patient at 2.39 mg/dL is approaching this threshold
  • However, do not stop these medications prematurely if the patient remains volume overloaded—persistent congestion is more harmful 1

• Digoxin: Re-evaluate dosing; check trough level and adjust to maintain <1 nmol/L 2

Step 5: Define Your Endpoint

Continue diuresis until clinical decongestion is achieved 1:

• Normalized jugular venous pressure
• Resolution of peripheral edema
• Stable or improving dyspnea
• Achievement of "dry weight"

Accept mild-to-moderate azotemia and hypotension as long as the patient remains asymptomatic 1. Excessive concern about rising creatinine leads to underutilization of diuretics and refractory edema, which worsens outcomes.

When to Worry vs. When Not to Worry

Don't Worry (Continue Diuresis) If:

• Creatinine rises <30% from baseline during active decongestion 2
• Patient is not oliguric
• Blood pressure remains adequate for perfusion
• Volume overload persists
• Even if creatinine rises during decongestion, this often improves survival compared to persistent congestion 3, 4

Do Worry (Reassess Strategy) If:

• Oliguria develops (urine output inadequate despite diuretics) 2
• Creatinine rises >50% from baseline 2
• Severe hypotension develops (systolic BP <90 mmHg with symptoms)
• Signs of true tubular injury appear (though rare in pure cardiorenal syndrome)

Advanced Options for Refractory Cases

If standard approaches fail 2:

1. Hypertonic saline + high-dose loop diuretic: Small studies suggest benefit, but requires expertise and close monitoring 2

2. Ultrafiltration: Consider in highly selected patients with:

   • Severe renal insufficiency
   • Persistent volume overload despite maximal medical therapy
   • Stable (not acute) renal dysfunction
   • Requires nephrology consultation 2

Common Pitfalls to Avoid

1. Stopping diuretics too early due to creatinine rise while congestion persists—this worsens outcomes 1

2. Using inadequate diuretic doses in the setting of reduced GFR—higher doses are often necessary 2

3. Failing to monitor electrolytes frequently when intensifying diuresis—check within 1-3 days in advanced HF 2

4. Not recognizing that volume depletion and hypotension are the most important reversible causes of worsening renal function—not the diuretics themselves 2

The Bottom Line

Your elderly patient with HFrEF and volume overload needs aggressive decongestion despite the AKI. The creatinine elevation likely reflects venous congestion and cardiorenal syndrome rather than intrinsic tubular damage 3, 4. Use continuous IV furosemide infusion, add a thiazide if needed, monitor closely, and continue until decongestion is achieved—even if creatinine rises further, as long as perfusion remains adequate and the patient is asymptomatic 1. This approach improves both short-term symptoms and long-term survival.